Navigation Links
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date:10/9/2009

relating to the offering was filed with the SEC on October 6, 2009. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained directly from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or from the SEC's website at www.sec.gov.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX fails to submit an ANX-530 NDA, whether by December 31, 2009 or at all; the risk the FDA will determine that ANX-530 and Navelbine® are not bioequivalent or for the FDA to require additional preclinical work and/or clinical activities to support the submiss
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
2. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
3. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
4. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
5. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
9. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
10. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 26, 2011 Revenue of $374 million grew 5 ... share were $0.55 compared to $0.31 in the prior year, an increase of ... points to 13.3 percent Fiscal year 2011 ... 7 percent and earnings are expected to be $2.18 to $2.26 per diluted ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported ... 31, 2010. The Company reported total revenue of $174.2 ... net product sales of $162.3 million and revenue under ... $22.9 million for the quarter ended December 31, 2010, ...
Cached Medicine Technology:Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 2Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 3Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 4Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 5Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 6Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 7Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 8Amylin Pharmaceuticals Reports 2010 Financial Results 2Amylin Pharmaceuticals Reports 2010 Financial Results 3Amylin Pharmaceuticals Reports 2010 Financial Results 4Amylin Pharmaceuticals Reports 2010 Financial Results 5Amylin Pharmaceuticals Reports 2010 Financial Results 6Amylin Pharmaceuticals Reports 2010 Financial Results 7Amylin Pharmaceuticals Reports 2010 Financial Results 8Amylin Pharmaceuticals Reports 2010 Financial Results 9
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Grieving children from northern Allegheny, Armstrong, Beaver, Butler, ... to be served at new facility, PITTSBURGH, Feb. ... Children, Adolescents and Their Families, announced today its,intention to ... Cranberry,area, which will aim to serve children and families ...
... For years, getting a lot of,calcium has been ... do to,prevent osteoporosis and related bone fractures. Small study ... the data from,large, prospective studies that followed people for ... 2008 issue of the Harvard,Health Letter., The ambiguity ...
... Americans who,are unaware they have diabetes or are at ... Risk Test, ALEXANDRIA, Va., Feb. 25 The ... WHAT: The American Diabetes Association will "sound the alert" ... Tuesday, March 25,2008. American Diabetes Alert Day is a ...
... reducing cross contaminations including Influenza and ... ... today introduced,the new SILVER SEAL(TM) Washable, Antimicrobial Mouse at the HiMSS,Healthcare Symposium ... world,s first computer mouse to be fully submersible,dishwasher safe, and manufactured from ...
... With Standardized Pomegranate Extract and Pomegranate Seed Oil ... and Cell Protecting Benefits, EL SEGUNDO, Calif., ... use of,pomegranate in skincare for anti-inflammatory, antioxidant and ... equal; it is,the quality of the extract that ...
... AS PART OF ... SMART HEART CHALLENGE CAMPAIGN, CHICAGO, Feb. 25 Quaker ... hearts. Thanks to thousands of,Americans who signed up to take the ... King Cardiac Foundation (LKCF).,As part of this heart healthy campaign to ...
Cached Medicine News:Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 2Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 3Health News:High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter 2Health News:Sound the Alert!!! - March 25 is the 20th Annual American Diabetes Alert(R) Day 2Health News:Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 3Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 2Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 3
... The ACS:180 SE is a ... PLUS, consisting of important physical ... simplify routine operation and increase ... the "Next Generation" ACS:180. The ...
... range of Platelet aggregometers allows to ... particular needs. Single, dual and four ... recorder outputs or digital computer outputs. ... aggregometers, which measure platelet aggregation in ...
... in achieving improved cost efficiency in ... cut costs is constantly increasing. Optimize ... unnecessary manual interactions. Ensuring security of ... mechanisms like pipetting integrity check. Right ...
... The Advia 2400 ... sample volume (as low ... water consumption (40 L/hour) ... The optional universal rack ...
Medicine Products: